<DOC>
	<DOCNO>NCT01056289</DOCNO>
	<brief_summary>Study Comparing Discontinuation Symptoms subject Major Depressive Disorder treat 24 Weeks Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation ( DVS SR )</brief_summary>
	<brief_title>Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Primary Diagnosis Major Depressive Disorder Hamilton Psychiatric Rating Scale Depression17Item score great equal 14 baseline Current psychoactive substance abuse dependence , manic episode , lifetime diagnosis bipolar psychotic disorder Potentially violent others significant risk suicide History current evidence gastrointestinal disease history surgery know interfere absorption excretion Known presence raise intraocular pressure history narrow angle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>